Objectives: To present recent scientific evidence on the effects of stem cell transplantation in animal models of neonatal hypoxic-ischemic brain injury and address the translational relevance of cell therapy for clinical application in this context.
Introduction
Neonatal hypoxic-ischemic (HI) brain injury is a major cause of neurological morbidity and mortality in infants.
Statistical data suggest an incidence of asphyxia of 2-4 per 1,000 full-term births. In Brazil, neonatal asphyxia is estimated to occur in approximately 2% of live births. 1 Furthermore, 20-50% of asphyxiated newborns die within the neonatal period, and up to 25% of survivors may exhibit permanent neuropsychological impairments, such as mental retardation, cerebral palsy, epilepsy, and learning disability. 2 The most frequent cause of HI encephalopathy is severe intrauterine asphyxia, and the main pathogenic mechanism attributed to its neuropathology is impaired cerebral blood flow. 3 Associated neurotoxic events, such as Use of stem cells in perinatal asphyxia: from bench to bedside Simone de Paula, 1 Samuel Greggio, 1 Jaderson Costa DaCosta 2 energy failure, membrane depolarization, excitatory amino acid release, accumulation of free radicals, and apoptosis, occur simultaneously and contribute to cellular dysfunction and neuronal death after HI insults. 4 Despite the technological and scientific advances in perinatal care of at-risk newborns, the clinical management of asphyxiated infants has been limited to maintenance of oxygenation, control of blood pressure and homeostasis, treatment of seizures, and control of intracranial hypertension. 5 New neuroprotective strategies have been investigated in experimental studies and clinical trials due to the clinical significance and socioeconomic impact generated by neonatal brain damage. Calcium blockers, inhibitors of excitatory amino acids and free radicals, use of nitric oxide, growth factors, neuropeptides and hypothermia are some of the current therapeutic approaches that aim to interrupt the cascade of neurochemical events triggered by hypoxiaischemia. 4 Except for hypothermia, which shows satisfactory outcomes only in infants with moderate HI injury, these therapies have limited results. 6 In this context, cell therapy has been explored because it is an up-to-date and promising approach for treatment epilepsy, and spinal cord injury. [10] [11] [12] [13] [14] Basically, stem cells that have been used in experimental studies of neonatal HI injury fall into two categories: neural stem cells from neuronal embryonic or adult tissue; and somatic stem cells of non-neural origin, particularly those isolated from bone marrow and umbilical cord blood.
The objective of this review was to present the state of the art of experimental studies of cell therapy in animal models of neonatal HI brain injury (Table 1) , addressing potential mechanisms of action of this therapeutic resource and the translational relevance of stem cell transplantation for clinical application in HI encephalopathy.
Transplantation of fetal neocortical tissue
In 1996, Elsayed et al. 15 conducted the first study on the use of cellular resources in the treatment of experimental HI brain injury. In that investigation, the authors assessed the effects of intracerebral transplantation of fetal neocortical tissue blocks performed 7 days after induction of HI brain injury in neonatal rats. Although successful transplants were observed in 63% of cases, the study failed to demonstrate significant therapeutic effects on brain atrophy. Additionally, that study did not conduct a functional assessment of transplanted animals. Another research group also performed intracerebral transplantation of fetal neocortical tissue 3 days after induction of HI brain injury. 16 Instead of using tissue blocks, the authors used cell suspensions to facilitate the transplantation procedure. The results showed improvement in motor function and asymmetry in treated animals. However, although transplants were identifiable in 72% of the animals 10-12 weeks after implantation, the authors observed absence of cortical cytoarchitecture recovery. These data indicate that HI brain tissue shows physiological processes that can attract astrocytic stem cells to the site of injury, as well as induce neuronal differentiation. Table 1 Review of publications on stem cell therapy in experimental hypoxia-ischemia in the neonatal period BDNF = brain-derived neurotrophic factor; BHK-GDNF = baby hamster kidney cells (BHK) transfected with glial cell line-derived neurotrophic factor (GDNF) complementary DNA; MAPC = multipotent adult progenitor cells; ChABC = chondroitinase ABC; HUCBSC = human umbilical cord blood stem cells; MSC = mesenchymal stem cells; NSC = neural stem cells; CXCR4 = CXC chemokine receptor 4; FGF-2 = fibroblast growth factor 2; GDNF = glial cell line-derived neurotrophic factor; HI = hypoxia-ischemia; ic = intracerebral route; ica = intracardiac route; icv = intracerebroventricular route; ip = intraperitoneal route; iv = intravenous route; NA = not analyzed; NGF = nerve growth factor; NT3 = neurotrophin 3; P = postnatal day; PGA = polyglycolic acid; pT = post-transplantation; SDF-1 = stromal cell-derived factor 1; T-PX = transplantation on postnatal day X; NI = no immunosuppression; CT = contralateral transplant; IT = ipsilateral transplant; VEH = vehicle. * Treated animals vs. control animals. ↑ = increase. ↓ = reduction.
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Reference
Elsayed et al. 15 Jansen et al. 16 Park et al. 27 Imitola et al. 23 Katsuragi et al. 32 Katsuragi et al. 33 Zheng et al. 21 Meier 58 Park et al. 22 Park et al. 29 Ma et al. 24 Dayer et al. 30 Yasuhara et al. 57 Sato 38 Yasuhara et al. 40 PimentelCoelho et al. 37 Jenny et al. 31 van Velthoven et al. 56 Lee et al. 55 Xia In an elegant study, Park et al. 22 However, the authors found no restorative effects on the structural brain damage. 25 The remaining ischemic environment can influence tissue The first study to test the effect of HUCBSC transplantation in HI rats was performed by Meier et al. 36 The authors primitive reflexes in these animals. 37 In addition, the authors demonstrated reduced cell death in the striatum and an anti-inflammatory effect in the cortex. However, the presence of few transplanted cells could be observed in the ischemic striatum and cortex of treated animals.
That same year, our research group published a study on the effects of intravenous delivery of HUCBSC in an experimental model of HI brain injury. 38 In parallel, we also developed an experimental model of hypoxia-ischemia in newborn piglets for the study of cell therapy in medium-sized animals. 39 Newborn pigs that received HUCBSC via the common carotid artery showed better neurological scores compared to animals subjected only to the HI injury model or the group transplanted via the umbilical artery. Additionally, the presence of few transplanted cells could be observed only in some animals in the group transplanted via the carotid artery.
An interesting study showed that intravenous injection of HUCBSC 7 days after HI brain injury, improved motor coordination and asymmetry in treated rats. 40 In the clinical setting, researchers at the Duke University have initiated a phase I study with autologous umbilical cord blood grafts in full-term newborns with moderate-tosevere HI encephalopathy (NCT00593242). Children will be followed for assessment of neurodevelopmental outcomes and subjected to magnetic resonance imaging. Currently, the clinical trial is in the process of recruiting patients who meet the selection criteria of the study.
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Mechanism of action Description
Cell 50 This cell type has an increased capacity to express neuronal phenotypes in vitro 51, 52 and in vivo. 53, 54 Recently injury have yet to be established.
Cell transdifferentiation
The first hypothesis examined to justify the beneficial 65 reported a 15% increase in the production of trophic factors in the circulating blood of adult rats subjected to cerebral ischemia after HUCBSC transplantation. Recently, the same group has reported similar results after stem cell transplantation in a neonatal HI injury model in rats. 40 Although endogenous release of trophic factors by neuronal tissue occurs in response to ischemic injury, this compensatory mechanism is insufficient to promote tissue regeneration and/or functional recovery.
Therefore, the authors of these studies suggest that the increase of specific trophic factors occurs probably due to the transplantation of stem cells.
Stimulation of endogenous neurogenesis
Several studies have demonstrated increased endogenous neurogenesis in response to neonatal HI injury. 66, 67 However, transplanted stem cells are believed to potentiate these intrinsic mechanisms of repair. In the study by van Velthoven et al., 56 transplantation of stem cells into HI animals was shown to reduce microglial proliferation and increase neurogenesis. The authors suggest that the transplanted cells had the ability to modulate post-HI injury inflammatory response, thus facilitating the process of endogenous neurogenesis.
Modulation of the inflammatory process
While beneficial to the recruitment and migration of stem cells to the site of injury, inflammatory process determined by brain damage appears to be restrictive for cell differentiation. 23 In this context, recent studies have shown that different sources of stem cells can inhibit the activation of various immune cells. Pluchino et al. 68 showed that NSC promoted neuroprotection through antiinflammatory cytokines and immunomodulatory molecules.
In another study, intravenous injection of HUCBSC increased the survival of neuronal tissue and reduced leukocyte infiltration and expression of proinflammatory proteins in the ischemic brain. 69 In 
Stimulation of angiogenesis
Some studies of ischemic injury in adult rats have shown increased vascularization in the penumbra within a few days after transplantation of stem cells. 72, 73 Furthermore, transdifferentiation of transplanted stem cells into new blood vessels (angiogenesis) has been observed. 34, 74 It is also likely that indirect cellular events occur in blood vessel formation. Chen et al. 75 showed that stem cells from the bone marrow stroma promoted angiogenesis in the ischemic region by increasing the endogenous levels of vascular endothelial growth factor. To date, there is only one study indicating neovascularization of brain tissue in HI animals that received NSC transplants. 27 The authors suggest that post-transplantation angiogenic signals were generated, thus allowing the formation of a new and vascularized parenchyma at the site of the porencephalic cyst.
Induction of neuroplasticity
Neuroplastic events include an increase in afferent and efferent connections between the site of injury and brain regions, restoring local synaptic activity by synaptogenesis. 34 The expression of synaptic proteins has been recently observed in adult rats with ischemic brain injury undergoing stem cell transplantation, which indicates the formation of synaptic contacts. 76, 77 Confirming this possibility, a recent study showed that intracerebral transplantation of NSC in HI rats increased the number of axon terminals in the sensorimotor cortex, corpus callosum, and ipsilateral striatum/thalamus as well as enhanced axonal sprouting into the injured hemisphere. 25 Stem cells in perinatal asphyxia -de Paula S et al.
Aspect Advantages Disadvantages
Route of delivery 
Translational aspects of cell therapy in perinatal asphyxia
Translational research can be defined as a process which leads from evidence-based medicine to sustainable solutions for public health problems. 78 Preclinical studies are the first step in developing new therapies. However, the transfer of knowledge acquired through studies in vitro and in animal models of HI brain injury to the clinical use of cell therapy requires attention to differences between species and critical analysis of experimental results. Moreover, aspects still poorly understood (Table 3) A recent meta-analysis demonstrated that intravenous cell delivery can improve outcomes in animal models of neurological disorders, and apoptosis inhibition is the main molecular change in the brain after transplantation. 81 Intravenous cell delivery is a less invasive, simple and safe procedure, allowing widespread distribution of transplanted cells to HI brain areas. 38, 40, 57 In addition, this procedure enables exposure of cells to chemotactic signals originating from the brain injury, which can selectively accumulate cells within the target tissue. 79, 82 However, only a small amount of stem cells may be able to reach the site of brain injury, since they can be trapped in the lungs, kidneys, liver, and spleen. Therefore, ectopic growth and toxicity in other organs need to be assessed before clinical use. 80 An alternative approach to avoid the systemic circulation system has been to deliver stem cells intra-arterially. Recent data show equally distributed migration and favorable neurological outcomes using this therapeutic approach in a rat model of HI brain injury. 55 This route bypasses the uptake by the systemic organs, allowing a large number of stem cells to reach the ischemic site, once vessels are reperfused. In the case of a permanent vascular occlusion, the transplanted cells will be distributed only in the penumbra region. 79 However, recent studies have reported high mortality rates with intraarterial delivery in HI transplanted animals, suggesting the formation of microvascular occlusion and ischemia. 79, 80, 83 In medical practice, this delivery method is commonly used in interventional vascular catheterization techniques. In a
Brazilian clinical trial of cell therapy in patients with chronic ischemic stroke (NCT00473057), promising results were observed after intra-arterial transplantation of autologous bone marrow stem cells. 46 The intraperitoneal route has also been used for cell transplantation in neonatal HI injury, demonstrating cell migration from the peritoneal cavity into the injured brain regions. 36, 37 The study findings suggest the presence of 
